Proactive Investors Interview – Algernon Pharmaceuticals Receives Positive Feedback On Its Planned Phase 1/2a DMT Human Stroke Stud

image of Proactive logo


Algernon Pharmaceuticals CEO Christopher J. Moreau joined Steve Darling from Proactive to share news regarding positive feedback received at a scientific advice meeting from the United Kingdom Medicines and Healthcare Products Regulatory Agency.

Mr. Moreau explains that the advice given is in regards to their planned Phase 1/2a stroke study with AP-188 or DMT. With this positive feedback, the Company is planning to conduct the Phase 1 part of the study at Hammersmith Medicines Research in the UK beginning in January 2022.